These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 11879549

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma.
    Brouwer R, Pruijn GJ, van Venrooij WJ.
    Arthritis Res; 2001; 3(2):102-6. PubMed ID: 11178117
    [Abstract] [Full Text] [Related]

  • 3. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
    Schilders G, Egberts WV, Raijmakers R, Pruijn GJ.
    Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?
    Mahler M, Fritzler MJ.
    Autoimmun Rev; 2009 Mar; 8(5):373-8. PubMed ID: 19103309
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The human exosome and disease.
    Staals RH, Pruijn GJ.
    Adv Exp Med Biol; 2011 Mar; 702():132-42. PubMed ID: 21713683
    [Abstract] [Full Text] [Related]

  • 8. The changing landscape of the clinical value of the PM/Scl autoantibody system.
    Mahler M, Fritzler MJ.
    Arthritis Res Ther; 2009 Mar; 11(2):106. PubMed ID: 19351430
    [Abstract] [Full Text] [Related]

  • 9. Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis.
    Villalta D, Morozzi G, Tampoia M, Alpini C, Brusca I, Salgarolo V, Papisch W, Bizzaro N.
    Clin Chim Acta; 2010 May 02; 411(9-10):710-3. PubMed ID: 20138166
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF.
    J Rheumatol; 2010 May 02; 37(5):1000-9. PubMed ID: 20231208
    [Abstract] [Full Text] [Related]

  • 12. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights.
    Mahler M, Raijmakers R.
    Autoimmun Rev; 2007 Aug 02; 6(7):432-7. PubMed ID: 17643929
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.
    Hanke K, Brückner CS, Dähnrich C, Huscher D, Komorowski L, Meyer W, Janssen A, Backhaus M, Becker M, Kill A, Egerer K, Burmester GR, Hiepe F, Schlumberger W, Riemekasten G.
    Arthritis Res Ther; 2009 Aug 02; 11(1):R22. PubMed ID: 19220911
    [Abstract] [Full Text] [Related]

  • 16. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients.
    D'Aoust J, Hudson M, Tatibouet S, Wick J, Canadian Scleroderma Research Group, Mahler M, Baron M, Fritzler MJ.
    Arthritis Rheumatol; 2014 Jun 02; 66(6):1608-15. PubMed ID: 24577935
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen.
    Mahler M, Raijmakers R, Dähnrich C, Blüthner M, Fritzler MJ.
    Arthritis Res Ther; 2005 Jun 02; 7(3):R704-13. PubMed ID: 15899056
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.